市場調查報告書
商品編碼
1287627
不孕症藥物市場:2023-2028年全球行業趨勢、佔有率、規模、成長、機會和預測Infertility Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028 |
2022年,全球不孕症藥物市場規模達到38億美元。展望未來,IMARC集團預計,到2028年,市場規模將達到52億美元,在2023-2028年期間表現出5.24%的成長率(CAGR)。
不孕症藥物是指用於治療不孕症和提高個人生殖健康的各種藥物。包括注射或口服。一些常用的不孕症藥物包括促性腺激素、芳香酶抑製劑、選擇性雌激素受體調節劑(SERM)、雙胍類藥物、排卵刺激劑、多巴胺激動劑和三環類抗抑鬱藥。作用是刺激女性的排卵和卵巢的卵泡發育,有助於恢復男性的睾丸激素水準並提高精子的品質,而實現懷孕。近年來,不孕症藥物在無法受孕的夫婦中得到了重視。
不孕症藥物透過恢復個人促進受孕的能力,協助提高夫妻懷孕的機會。因此,不孕症和流產的發生率上升是推動市場成長的主要因素。除此之外,各國政府採取了一些有利的計劃,以傳播有關現有治療方案的意識,催化對不孕症藥物的需求。此外,由於繁忙的工作安排、伴隨的壓力和生活方式的改變,慢性疾病的發病率有了明顯的增加,如癌症、肥胖、糖尿病、甲狀腺、多囊卵巢綜合症(PCOS)和更年期障礙。與此同時,由於延遲懷孕、晚婚和不健康的生活習慣,如過度飲酒、吸毒和吸煙,促使生育率下降,加速產品的採用率。此外,一些主要參與者從事研究和開發(R&D)活動,以推出療效更好、劑量要求更低、副作用更少的創新型不孕症藥物。此外,用於開發這些藥物的公共資金不斷增加,各監管機構對藥物的審批速度加快,這些都推動了市場的成長。其他因素,包括對學名藥需求的升級、醫療基礎設施的改善、消費者支出能力的提高、快速城市化和技術進步,也為市場成長提供了積極的推動力。
The global infertility drugs market size reached US$ 3.8 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 5.2 Billion by 2028, exhibiting a growth rate (CAGR) of 5.24% during 2023-2028.
Infertility drugs refer to various medications used to treat infertility and enhance the reproductive health of an individual. They are either injected or taken orally. Some commonly used infertility drugs include gonadotrophins, aromatase inhibitors, selective estrogen receptor modulators (SERMs), biguanides, ovulatory stimulants, dopamine agonists, and tricyclic antidepressants. They work by stimulating ovulation and follicle development of the ovary in women, whereas they help restore testosterone levels and improve the quality of sperm in men to bring about pregnancy. In recent years, infertility drugs have gained traction among couples who are unable to conceive.
Infertility drugs assist in enhancing the chances of pregnancy in couples by restoring the ability of an individual to contribute to conception. As a result, the rising incidences of infertility and miscarriage represents the primary factor driving the market growth. Besides this, several favorable initiatives undertaken by governments of various countries to spread awareness regarding the available treatment options are catalyzing the demand for infertility drugs. Additionally, there has been a significant increase in the prevalence of chronic diseases, such as cancer, obesity, diabetes, thyroid, polycystic ovarian syndrome (PCOS), and menopausal disorders, on account of hectic work schedules, accompanying stress, and lifestyle changes. Along with this, the declining fertility rates due to delayed pregnancies, late marriages, and unhealthy habits, such as excessive consumption of alcohol, drugs, and smoking, are accelerating the product adoption rates. Furthermore, several key players are engaging in research and development (R&D) activities to launch innovative infertility drugs with enhanced efficacy, lower dosage requirements, and fewer side effects. Moreover, the increasing public funding for developing these drugs and faster drug approvals from various regulatory bodies are propelling the market growth. Other factors, including the escalating demand for generic medicines, improving healthcare infrastructure, rising consumer expenditure capacities, rapid urbanization, and technological advancements, are also providing a positive thrust to the market growth.
IMARC Group provides an analysis of the key trends in each sub-segment of the global infertility drugs market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on drug class, route of administration, distribution channel and end user.
Gonadotropin
Aromatase Inhibitors
Selective Estrogen Receptor Modulators (SERMs)
Biguanides
Others
Oral
Intravenous
Subcutaneous
Intramuscular
Hospital Pharmacies
Retail Pharmacies
Others
Male
Female
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Bayer AG, Ferring Pharmaceuticals, Livzon Pharmaceutical Group Inc., Mankind Pharma, Merck & Co. Inc., Merck KGaA, Novartis AG, Pfizer Inc., Sanofi S.A. and Theramex.